secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001193125-25-157388
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair
--------------------------------------------------------------------------------

- Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.
- Bruce Cozadd retires as CEO on Aug 11, transitions to advisor through Sep 12, then remains Chairperson.
- Gala's base salary increases to $1.2M (from $900k); target bonus rises to 110% of salary (from 80%).
- Gala receives a one-time promotion equity grant of ~$6.5M (33% RSUs, 67% PSUs) on top of $6M annual grant.
- Severance enhanced: lump sum of 150% base salary (was 100%) and COBRA coverage extended to 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525157388/0001193125-25-157388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525157388/d15137d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer